Agile Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>AT</div>
AGRX -- USA Stock  

USD 3.69  0.09  2.38%

Agile Therapeutics is scheduled to announce its earnings today. The next earnings report is expected on the 26th of October 2020. As many retail investors are getting excited about healthcare space, it is fair to break down Agile Therapeutics outlook under the current economic conditions. I will address why investors ignored this entity since the beginning of the current economic outlook.
Published over a month ago
View all stories for Agile Therapeutics | View All Stories
Will Agile Therapeutics (NASDAQ:AGRX) investors continue to trust the experts consensus?
Agile Therapeutics is UNDERVALUED at 3.79 per share with modest projections ahead. We provide trade advice to complement the prevailing expert consensus on Agile Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Agile Therapeutics? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Agile Therapeutics this year

Annual and quarterly reports issued by Agile Therapeutics are formal financial statements that are published yearly and quarterly and sent to Agile stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Agile Therapeutics often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Agile utilizes its cash?

To perform a cash flow analysis of Agile Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Agile Therapeutics is receiving and how much cash it distributes out in a given period. The Agile Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Agile Therapeutics Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Agile Therapeutics reported Net Cash Flow from Operations of (15.69 Million) in 2019

Exercise or conversion by Dennis Reilly of 37500 shares of Agile Therapeutics subject to Rule 16b-3

Legal trades by Agile Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Agile insider trading alert for exercise of employee stock option (right to buy) by Dennis Reilly, Chief Financial Officer, on 26th of August 2020. This event was filed by Agile Therapeutics Inc with SEC on 2020-08-26. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Agile a risky opportunity?

Let's check the volatility. Agile is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Agile (NASDAQ:AGRX) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of an Agile Therapeutics stock makes you a part-owner of that company.

Agile Therapeutics Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Agile Therapeutics. The Agile consensus assessment is calculated by taking the average estimates from all of the analysts covering Agile Therapeutics

Strong Buy
Strong Buy375.0
Strong Sell00.0

Some Agile technical indicators suggest turnaround

Downside variance is down to 10.94. It may suggest a possible volatility slide. Agile Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Agile Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Agile Therapeutics future alpha.

When is the right time to buy or sell Agile Therapeutics? Buying stocks such as Agile Therapeutics isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. To conclude, as of the 11th of August 2020, we see that Agile Therapeutics almost mirrors the market. The company is undervalued with low probability of distress within the next 24 months. Our present 30 days Buy-Hold-Sell recommendation on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Agile Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to